

Curriculum Vitae

Personal information **Irene Bosselaers**

Work experience

1. Employer: Medicines Evaluation Board (CBG_MEB)
 - Start date: 102021
 - End date:
 - Position: Assessor
 - Activities: Clinical Pharmacology
 - Country: Netherlands
2. Employer: Medicines Evaluation Board (CBG_MEB)
 - Start date: 062011
 - End date: 102021
 - Position: Assessor
 - Activities: Non_clinical assessment (pharmacology of anti_infective agents, pharmacokinetics, toxicology), clinical pharmacokinetics
 - Country: Netherlands
3. Employer: National Institute of Public Health and the Environment (RIVM)
 - Start date: 022002
 - End date: 062011
 - Position: Assessor
 - Activities: Non-clinical assessment
 - Country: Netherlands
4. Employer: Gimbrère & Dohmen
 - Start date: 1998
 - End date: 2002
 - Position: Computer programmer
 - Activities:
 - Country: Netherlands
5. Employer: RIKILT_DLO
 - Start date: 1995
 - End date: 1998
 - Position: Assessor of veterinary medicines
 - Activities:
 - Country: Netherlands

Education and training

1. Subject: Agricultural University of Wageningen
 - Start date: 1985
 - End date: 1991
 - Qualification: MSc in Human Nutrition
 - Organisation: Agricultural University Wageningen
 - Country: Netherlands

Additional information

Publications

Differential effects of milk proteins, BSA and soy protein on 4NQO_ or MNNG_induced SCEs in V79 cells. I.E.M. Bosselaers, P.W.J.R. Caessens, M.A.J.S. van Boekel and G.M. Alink. Food and Chemical Toxicology 1994;32:905_909. Twenty_four_hour energy expenditure and substrate utilization in body builders. I. Bosselaers, B. Buemann, O.J. Victor and A. Astrup. American Journal of Clinical Nutrition 1994;59:10_12 Nanomedicinal products: a survey on specific toxicity and side effects. Brand W, Noorlander CW, Giannakou C, de Jong WH, Kooi MW, Park MVDZ, Vandebriel RJ, Bosselaers IEM, Scholl JHG, Geertsma RE. Nanomedicinal products: a survey on specific toxicity and side effects. Int J Nanomedicine 12: 6107_6129, 2017. Nonclinical regulatory immunotoxicity testing of nanomedicinal products: Proposed strategy and possible pitfalls. Giannakou C, Park MVDZ, Bosselaers IEM, de Jong WH, van der Laan JW, van Loveren H, Vandebriel RJ, Geertsma RE. WIREs Nanomed Nanobiotechnol 2020; e1633. <https://doi.org/10.1002/wnan.1633>

Projects

Memberships

Other Relevant Information